OSI Pharmaceuticals (OSIP) - formerly Oncogene

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
OSI Pharmaceuticals (OSIP) - formerly Oncogene

An SI Board Since December 1997

Posts	SubjectMarks	Bans	Symbol
447	40	0	OSIP

Emcee: James Reynolds	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
272	From Genentech's quarterly PR just out: >>U.S. sales of Tarceva®	tuck	-	10/10/2005
271	>>J Clin Oncol. 2005 Oct 3; [Epub ahead of print] Treatment of Metasta	tuck	-	10/10/2005
270	I guess, numbers are %-tage of market potential. Still, I would expect growth in	Miljenko Zuanic	-	10/6/2005
269	>How much Tarceva penetrated second line treatment, is real thing for future	former_pgs	-	10/6/2005
268	It doesn't have to be all financially driven. Why would any of of us change	kenhott	-	10/6/2005
267	The fact that Tarceva is an oral drug may -- perversely -- work against it. I t	tuck	-	10/6/2005
266	So far, total Rx trend does not indicate significant LONGER use of Terceva versu	Miljenko Zuanic	-	10/6/2005
265	Could also be that recent scrip data looks OK: finance.messages.yahoo.com Chee	tuck	-	10/5/2005
264	More likely what's helping OSIP this morning is this from Morgan Stanley via	tuck	-	10/5/2005
263	Macugen seems to help early sage wet AMD patients more. Shaky looking subgroup	tuck	-	10/5/2005
262	Slightly dated scrip data on Tarceva: finance.messages.yahoo.com Cheers, Tuck	tuck	-	10/4/2005
261	Dr. Colin Goddard: There's an outstanding question, one that absolutely fas	scaram(o)uche	-	9/22/2005
260	European Approval of tarceva for NSCLC: >>MELVILLE, N.Y.--(BUSINESS WIRE)	tuck	-	9/21/2005
259	[Phase II Study of Tarceva in Patients With Advanced Hepatocellular Cancer ] &g	tuck	-	9/20/2005
258	Goddard: clinicaltrials.gov	scaram(o)uche	-	9/19/2005
257	>>MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 15, 2005--OSI Pharmaceuticals, In	tuck	-	9/15/2005
256	Merrill OSI Pharmaceuticals, Inc. Company Update; Panel Favors Tarceva; Use M	tom pope	-	9/14/2005
255	Here is the briefing document for tomorrow's ODAC meeting, if anyone is inte	FiloF	-	9/12/2005
254	[In vitro study of OSI-930] >>Mol Cancer Ther. 2005;4:1186-1197 Temporal	tuck	-	8/15/2005
253	[PI for OSI-7904L] >>Clinical Cancer Research Vol. 11, 5487-5495, August	tuck	-	8/15/2005
252	>>Same thing?<< Clearly. Same PI, same results. Cheers, Tuck	tuck	-	7/15/2005
251	Same thing? <i>TORONTO (CP) - A new drug has been found, for the first ti	tom pope	-	7/14/2005
250	Message 21504535	scaram(o)uche	-	7/14/2005
249	>>MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--July	tuck	-	7/13/2005
248	Files sNDA for advanced pancreatic (with Gemzar): >>MELVILLE, N.Y.--(BUSI	tuck	-	7/6/2005

Go to reply# or date (mm/dd/yy):